European Patent Office: End of self-collision

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

European Patent Office: End of self-collision

Towards the end of November 2016, the Enlarged Board of Appeal of the European Patent Office rendered its order in decision G 1/15, which brings an end to the phenomenon of so-called self-collision, also nicknamed toxic divisionals and poisonous priorities. On the date of completion of this article, the reasons for the decision have not been made available. The Enlarged Board's order is, however, clear in the sense that applicants no longer have to worry about self-collision.

The question addressed by the Enlarged Board relates to the citability under Article 54(3) EPC of a parent application against its own divisional or vice versa. Such citability is in principle possible if one of the parent or divisional applications includes specific disclosure, which is also disclosed in the priority document, and which is embraced by a generic claim in the other one of the parent and divisional. If such a generic claim is not entitled to priority in its entire scope, the generic claim would lose its entitlement to priority, in which case the specific disclosure in the parallel application would take away the novelty of the generic claim.

According to the Enlarged Board's order of November 29 2016: "Entitlement to partial priority may not be refused for a claim encompassing alternative subject-matter by virtue of one or more generic expressions or otherwise (generic 'OR'-claim) provided that said alternative subject-matter has been disclosed for the first time, directly, or at least implicitly, unambiguously and in an enabling manner in the priority document. No other substantive conditions or limitations apply in this respect." In other words, a generic claim may enjoy partial priority for alternatives specifically disclosed in the priority document. As a result, there is no need any more for applicants to consider self-collision as a potential risk in relation to divisional applications, or in other instances of parallel applications sharing a common priority.

frederiksen.jpg

Jakob Pade Frederiksen

Inspicos P/S

Kogle Allé 2

DK-2970 Hoersholm

Copenhagen, Denmark

Tel: +45 7070 2422

Fax: +45 7070 2423

info@inspicos.com

www.inspicos.com

more from across site and SHARED ros bottom lb

More from across our site

Licensing chief Patrik Hammarén also reveals that the company will rename its IPR business to better reflect its role in defining standards
The acquisition of Pecher & Partners follows the firm’s earlier expansion into litigation to create a ‘one-stop shop’
News of Via Licensing Alliance launching its first semiconductor patent pool and INTA electing a new president were also among the top talking points
Submit your nominations to this year's WIBL Americas Awards by January 23
The 2026 Life Sciences EMEA Awards is now open for entries. We are looking forward to reviewing and celebrating the industry's most impressive achievements and landmarks from the past year.
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
A dispute involving semiconductor technology and a partner's move from Hoffman Eitle to Hoyng Rokh Monegier were also among the top talking points
Gift this article